Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib in ATM-altered advanced cancer (PLANETTE)
NCT04564027Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of ceralasertib in solid tumor (advanced stage) and metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Objective Response Rate and Composite Response Rate. Started Dec 2020; status: completed.
02
Drugs
ceralasertib
03
Conditions
solid tumor (advanced stage)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04564027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564027.